Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in Bipolar Depression and Obesity
NCT07699445Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lumateperone in bipolar disorder (BD), sponsored by Massachusetts General Hospital. Primary endpoints: Montgomery Asberg Depression Rating Scale at 6 weeks and Inflammatory Markers at 6 weeks. Started Sep 2026; status: recruiting.
02
Drugs
lumateperone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07699445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07699445.